Sam Brusco, Associate Editor09.22.22
QT Imaging has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its QTScan tool to calculate the breast’s fibroglandular volume (FGV) and ratio of FGV to total breast volume (TGV).
The ratio can help to assess risk of breast cancer. Changes in the ratio can also be used to measure efficacy of medication to treat or prevent breast cancer.
QTScan doesn’t require radiation, injection, or compression. According to the company, no other ultrasound-based breast imaging modality is FDA-cleared to quantify fibroglandular volume.
"The ability to determine a therapeutic clinical response using a quantitative volumetric method is crucial for effective and timely treatment of breast cancer and for patients at high risk for developing breast cancer who are receiving hormonal therapy. The FGV tool will allow this assessment to be made early and in follow-up to maximize treatment benefit, which is an exciting development for breast care patients," Dr. Elaine Iuanow, a breast imaging specialist and medical consultant for QT Imaging told the press.
"We are excited to expand the tools available using low frequency transmitted ultrasound volography to serve women, especially those with dense breasts, providing an imaging option that is safe, comfortable, and effective," added Dr. John Klock, CEO, chief medical officer and founder of QT Imaging.
The ratio can help to assess risk of breast cancer. Changes in the ratio can also be used to measure efficacy of medication to treat or prevent breast cancer.
QTScan doesn’t require radiation, injection, or compression. According to the company, no other ultrasound-based breast imaging modality is FDA-cleared to quantify fibroglandular volume.
"The ability to determine a therapeutic clinical response using a quantitative volumetric method is crucial for effective and timely treatment of breast cancer and for patients at high risk for developing breast cancer who are receiving hormonal therapy. The FGV tool will allow this assessment to be made early and in follow-up to maximize treatment benefit, which is an exciting development for breast care patients," Dr. Elaine Iuanow, a breast imaging specialist and medical consultant for QT Imaging told the press.
"We are excited to expand the tools available using low frequency transmitted ultrasound volography to serve women, especially those with dense breasts, providing an imaging option that is safe, comfortable, and effective," added Dr. John Klock, CEO, chief medical officer and founder of QT Imaging.